Merck drug triggers response in 24 percent of lung cancer patients

[riky]

Merck drug triggers response in 24 percent of lung cancer patients

(Reuters) - Early data from a small trial of Merck & Co Inc's experimental immunotherapy cancer drug, known as MK-3475, showed that about a quarter of lung cancer patients responded to the treatment. Data from the trial is slated for presentation in Sydney, Australia, later this month at the World Conference on Lung Cancer, Merck said in a statement on Tuesday. The antibody drug, once known as lambrolizumab, is part of a new class of compounds designed to block the activity of a receptor on immune cells called programmed death 1 or PD-1. ...

Source: You are not allowed to view links. Register or Login